Prognostic and Clinicopathological Value of MUC1 Expression in Colorectal Cancer: A Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Mar 1

PMID 30817589

Citations 9

Authors

Chao Li

Tao Liu

Libin Yin

Didi Zuo

Yuyang Lin

Lei Wang

Affiliations

Soon will be listed here.

Abstract

Background: Accumulating evidence supports the overexpression of mucin 1 (MUC1) in colorectal cancer (CRC), but the value of elevated MUC1 expression remains controversial. Here, we evaluated the prognostic and clinicopathological value of MUC1 expression in CRC.

Materials And Methods: The Web of Science, PubMed, Embase, Cochrane Library, and Wanfang databases, as well as the China Biology Medicine disc (CBMdisc) and China National Knowledge Infrastructure (CNKI) were searched for studies on MUC1 expression and prognosis of CRC through July 20, 2018. The pooled relative risks (RRs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the prognostic and clinicopathological value of MUC1 expression in CRC. The Revman version 5.3 package and STATA, version 12 were employed for pooled analysis and analysis of publication bias.

Results: This meta-analysis included 16 published studies. The combined analysis showed that CRC patients with high MUC1 expression had a worse clinical outcome in overall survival (OS) (HR = 1.51, 95% CI = 1.30-1.75, P <.00001). In addition, high MUC1 expression was associated with higher TNM stage (RR = 1.44, 95% CI = 1.17-1.77, P = .0007), greater depth of invasion (RR = 1.30, 95% CI = 1.10-1.53, P = .002), and lymph node metastasis (RR = 1.47, 95% CI = 1.20-1.80, P = .0002) of CRC. However, the elevated MUC1 expression was not related to disease-free survival/recurrence-free survival (DFS/RFS) (HR = 1.51, 95% CI = 0.78-2.89, P = .22), histological grade (RR = 1.15, 95% CI = 0.96-1.38, P = .12), gender (RR = 0.95; 95% CI = 0.83-1.08, P = .44), tumor size (RR = 1.11, 95% CI = 0.85-1.44, P = .44), tumor site (RR = 1.01, 95% CI = 0.88-1.16, P = .84), or mucinous component (RR = 0.83, 95% CI = 0.60-1.14, P = .24) in CRC.

Conclusion: Our findings indicated that high MUC1 expression represents a marker of poor prognosis in CRC. Meanwhile, elevated MUC1 expression was associated with advanced TNM stage, greater depth of invasion, and lymph node metastasis.

Citing Articles

Markers of Epithelial-Mesenchymal Transition and Mucinous Histology Are Significant Predictors of Disease Severity and Tumor Characteristics in Early-Onset Colorectal Cancer.

Djikic Rom A, Dragicevic S, Jankovic R, Radojevic Skodric S, Sabljak P, Markovic V Diagnostics (Basel). 2024; 14(14).

PMID: 39061649 PMC: 11275501. DOI: 10.3390/diagnostics14141512.

Precision Oncology: Circulating Microvesicles as New Biomarkers in a Very Early Stage of Colorectal Cancer.

Kriebardis A, Chardalias L, Damaskos C, Pouliakis A, Garmpis N, Fortis S Cancers (Basel). 2024; 16(10).

PMID: 38792021 PMC: 11119677. DOI: 10.3390/cancers16101943.

Panaxynol alleviates colorectal cancer in a murine model via suppressing macrophages and inflammation.

McDonald S, Bullard B, VanderVeen B, Cardaci T, Huss A, Fan D Am J Physiol Gastrointest Liver Physiol. 2023; 325(4):G318-G333.

PMID: 37489869 PMC: 10642997. DOI: 10.1152/ajpgi.00119.2023.

The Mucin Family of Proteins: Candidates as Potential Biomarkers for Colon Cancer.

Cox K, Liu S, Lwin T, Hoffman R, Batra S, Bouvet M Cancers (Basel). 2023; 15(5).

PMID: 36900282 PMC: 10000725. DOI: 10.3390/cancers15051491.

Supplementation with sesame oil suppresses genotoxicity, hepatotoxicity and enterotoxicity induced by sodium arsenite in rats.

Akinrinde A, Oyewole S, Ola-Davies O Lipids Health Dis. 2023; 22(1):14.

PMID: 36707815 PMC: 9881342. DOI: 10.1186/s12944-022-01760-5.

References

Oshima T, Kawasaki T, Ohashi R, Hasegawa G, Jiang S, Umezu H . Downregulated P1 promoter-driven hepatocyte nuclear factor-4alpha expression in human colorectal carcinoma is a new prognostic factor against liver metastasis. Pathol Int. 2007; 57(2):82-90. DOI: 10.1111/j.1440-1827.2006.02061.x. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

Besmer D, Curry J, Roy L, Tinder T, Sahraei M, Schettini J . Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 2011; 71(13):4432-42. PMC: 3129481. DOI: 10.1158/0008-5472.CAN-10-4439. View

Ruys A, Groot Koerkamp B, Wiggers J, Klumpen H, Ten Kate F, van Gulik T . Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2013; 21(2):487-500. DOI: 10.1245/s10434-013-3286-x. View

Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K . Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol. 2007; 39(1):126-36. DOI: 10.1016/j.humpath.2007.05.027. View

Vandenhaute B, Buisine M, Debailleul V, Clement B, Moniaux N, Dieu M . Mucin gene expression in biliary epithelial cells. J Hepatol. 1998; 27(6):1057-66. DOI: 10.1016/s0168-8278(97)80150-x. View

Lee H, Lee H, Kim H, Yang H, Kim Y, Kim W . MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas: their roles as prognostic indicators. Cancer. 2001; 92(6):1427-34. DOI: 10.1002/1097-0142(20010915)92:6<1427::aid-cncr1466>3.0.co;2-l. View

Liu S, Ruan M, Li S, Wang L, Yang W . Increased expression of MUC1 predicts poor survival in salivary gland mucoepidermoid carcinoma. J Craniomaxillofac Surg. 2014; 42(8):1891-6. DOI: 10.1016/j.jcms.2014.07.008. View

Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M . Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 2002; 94(6):1770-6. DOI: 10.1002/cncr.10398. View

10.

Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F . Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol. 1999; 16(1):55-64. DOI: 10.3892/ijo.16.1.55. View

11.

Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G . Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology. 1998; 55(4):307-19. DOI: 10.1159/000011868. View

12.

Paul D, Kumar A, Gajbhiye A, Santra M, Srikanth R . Mass spectrometry-based proteomics in molecular diagnostics: discovery of cancer biomarkers using tissue culture. Biomed Res Int. 2013; 2013:783131. PMC: 3613068. DOI: 10.1155/2013/783131. View

13.

Kitamoto S, Yokoyama S, Higashi M, Yamada N, Takao S, Yonezawa S . MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors. Oncogene. 2012; 32(39):4614-21. DOI: 10.1038/onc.2012.478. View

14.

de Bono J, Rha S, Stephenson J, Schultes B, Monroe P, Eckhardt G . Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004; 15(12):1825-33. DOI: 10.1093/annonc/mdh472. View

15.

Deng J, Wang L, Chen H, Li L, Ma Y, Ni J . The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer Metastasis Rev. 2013; 32(3-4):535-51. DOI: 10.1007/s10555-013-9423-y. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45(Pt A):139-45. PMC: 4639420. DOI: 10.1016/j.cct.2015.09.002. View

17.

Wang X, Kong F, Mai W, Li L, Pang L . MUC1 Immunohistochemical Expression as a Prognostic Factor in Gastric Cancer: Meta-Analysis. Dis Markers. 2016; 2016:9421571. PMC: 4852113. DOI: 10.1155/2016/9421571. View

18.

Gonzalez-Pons M, Cruz-Correa M . Colorectal Cancer Biomarkers: Where Are We Now?. Biomed Res Int. 2015; 2015:149014. PMC: 4461726. DOI: 10.1155/2015/149014. View

19.

Sahraei M, Roy L, Curry J, Teresa T, Nath S, Besmer D . MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene. 2012; 31(47):4935-45. PMC: 3337953. DOI: 10.1038/onc.2011.651. View

20.

Compton C . Optimal pathologic staging: defining stage II disease. Clin Cancer Res. 2007; 13(22 Pt 2):6862s-70s. DOI: 10.1158/1078-0432.CCR-07-1398. View